Diffuse laser treatment for prophylaxis of the fellow eye with age-related maculopathy in patients with exudative age-related macular degeneration (AMD)

ISRCTN ISRCTN74548520
DOI https://doi.org/10.1186/ISRCTN74548520
Secondary identifying numbers N0116169807
Submission date
29/09/2006
Registration date
29/09/2006
Last edited
15/04/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Mr NHV Chong
Scientific

Denmark Hill
Camberwell
London
SE5 9RS
United Kingdom

Phone +44 020 7737 4548
Email victor@eretina.com

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typePrevention
Scientific titleDiffuse laser treatment for prophylaxis of the fellow eye with age-related maculopathy in patients with exudative age-related macular degeneration (AMD)
Study objectivesAge-related macular degeneration (AMD) is the leading cause of blindness in the developed world. The formation of abnormal blood vessels (Choroidal Neovascular Vessels = CNV) under the retina is the main cause of visual loss. It is often referred to as 'wet' AMD. Once the first eye is affected, the other eye has a high risk of developing the disease. This risk is increased (>70% in 5 years) if the fellow eye has signs of early disease in the form of yellow deposits known as drusen.
Drusen disappear in over 60% of eyes treated with focal laser treatment. However, this type of laser can cause focal damage to the eye leading to a slight increase risk of developing CNV. Nonetheless, those who do not develop this complication, have better vision.
We propose to use diffuse laser treatment to make drusen disappear, in which laser energy is transmitted to a larger area of the retina. As the laser energy is applied diffusely, it is unlikely to cause focal damage and hence it is possible that this can reduce the risk of developing CNV. Diffuse laser is has previously been used as a treatment for wet AMD, and it has been shown to be a safe procedure.

The aim of this study is to evaluate whether diffuse laser treatment reduce the rate of CNV development in the fellow eye of patients with wet AMD and hence maintain stable vision.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedEye Diseases: Age-related macular degeneration (AMD)
InterventionAge-related macular degeneration (AMD) is one of the leading causes of blindness in the western world. Currently there is no cure for this disease and treatment options for stabilising the vision are limited and expensive.
AMD can be identified in its early stages by the appearance of pigment changes and yellow deposits (drusen) which form in the macular. At this stage the patient usually has minimal symptoms. There is however a high risk of CNV formation which is the blinding condition. We would like to enrol patients at the early stage of the disease to see if our proposed treatment will reduce their risk of converting to CNV.
Eligible patients will be referred to the principle investigator for the project who will explain the aims and limitations of the study including the background data, study design and relevant risks and benefits. Written informed consent will be obtained and a patient information leaflet including contact numbers will be given to the patient. A letter explaining the details and enrolment into the trial will be sent to the GP.
Patients will be asked to attend the outpatient clinic on day 1 (baseline) with follow up at 6 monthly intervals for the first year and yearly for the second year.
The baseline visit will include documentation of visual acuity, complete ocular examination, colour fundus photography, taking a single serum sample for analysis followed by randomisation to either diffuse laser treatment or placebo treatment of the fellow eye.
The diffuse laser treatment or placebo will involve instillation of topical anaesthetic drops followed by placing a laser contact lens on the eye to be treated. A diode laser using 3000 micron spot size at 400mW (active treatment) or 0mW (placebo) is applied for 60 seconds centred on the fovea. No after care is required.
Follow up appointments will be carried out by a masked observer with repeat documentation of the visual acuity, colour fundus photography. Repeat serum sample is taken at exit from the trial. All visual symptoms are documented and a complete dilated ocular examination will be performed.
The rate of conversion to CNV will be documented and confirmed using fundus fluoresceine angiogram.
Intervention typeOther
Primary outcome measureRate of development of CNV
Secondary outcome measuresNot provided at time of registration
Overall study start date01/07/2005
Completion date01/01/2009

Eligibility

Participant type(s)Patient
Age groupSenior
SexNot Specified
Target number of participantsNot provided at time of registration
Key inclusion criteriaOutpatients aged 55 or over with a diagnosis of exudative age-related macular degeneration in one eye and early changes of AMD (drusen and retinal pigment changes) in the other eye
Key exclusion criteria1. Patients in whom colour fundus photography is not possible due to ocular media opacities or other disabilities
2. Those with other retinal diseases.
Date of first enrolment01/07/2005
Date of final enrolment01/01/2009

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Denmark Hill
London
SE5 9RS
United Kingdom

Sponsor information

Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Government

The Department of Health, Richmond House, 79 Whitehall
London
SW1A 2NL
United Kingdom

Phone +44 (0)20 7307 2622
Email dhmail@doh.gsi.org.uk
Website http://www.dh.gov.uk/Home/fs/en

Funders

Funder type

Government

Kings College Hospital NHS Trust R&D Consortium

No information available

Own Account

No information available

NHS R&D Support Funding

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

Editorial Notes
15/04/2016: No publications found, verifying study status with principal investigator.